Phase 2 N=116 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Adult Rhabdomyosarcoma · Adult Synovial Sarcoma · Childhood Hepatoblastoma
Primary: Disease Response — 10; 10; 19; 10 patient
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Recurrent Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: MTD/RP2D of Pevonedistat in Combination With Irinotecan and Temozolomide — 35 mg/m^2
Phase 2 N=35 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
Phase 2 N=19 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Phase 2 N=140 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Metastatic Melanoma · Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Recurrent Hodgkin Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab — 0; 0; 5; 0 Participants
Phase 2 N=56 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Metastatic Osteosarcoma · Recurrent Osteosarcoma · Refractory Osteosarcoma
Primary: Disease Control Rate (Cohort I) — 1 participants
Phase 2 N=59 Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma
Primary: Response Rate — 15.3 percentage of participants
Phase 2 N=26 Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Phase 2 N=139 RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Small Cell Carcinoma · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors
Primary: Overall Survival — 6.85; 7.6; 7.5 Months
Phase 2 N=52 Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors
Solid Tumor, Adult
Primary: Immune-related Objective Response Rate — 9 Participants
Phase 2 N=29 Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 3; 15; 5 Participants
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 1 N=27 Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Recommended Dose of PDX Given With a Fixed Dose of 5-FU — 148 mg per meter square
Phase 2 N=20 Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Best Overall Response Rate (ORR) — 2 Participants
Phase 2 N=123 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Adult Glioblastoma · Adult Gliosarcoma · Recurrent Adult Brain Neoplasm
Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants
Phase 2 N=48 Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
Phase 2 N=20 Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
Skin Squamous Cell Carcinoma · Appendix Adenocarcinoma · Rare Lesion
Primary: Overall Response Rate (ORR) — 2 Participants
Phase 2 N=3 Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma
Primary: Objective Response Rate (ORR) — 2; 0 Participants
Phase 2 N=26 Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
Tumors
Primary: Maximum Tolerated Dose (MTD) of Single Agent Metronomic Oral Topotecan — 1.0 mg/day
Phase 2 N=16 Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Cancer
Primary: Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin — 0; 0; 0; 0 Participants
Phase 2 N=19 Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Recurrent Osteosarcoma
Primary: Disease Control Success — 0 participants
Phase 1 N=29 A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Pediatric Solid Tumor · Refractory Tumor · Recurrent Tumor
Primary: Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab — 1; 1 Participants
Phase 2 N=4 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Phase 2 N=20 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Phase 2 N=40 Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Adult Solid Neoplasm · Childhood Solid Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: The Number of Participants With Dose Limiting Toxicities to Determine the Maximum Tolerated Dose of Temozolomide and Talazoparib Combination Therapy — 0; 0; 1; 2…
Phase 1 N=55 Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Advanced Malignant Solid Neoplasm · Fibrolamellar Carcinoma · Metastatic Malignant Solid Neoplasm
Primary: Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
Phase 2 N=20 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Mixed Gliomas
Primary: Number of Participants With Objective Response — 3; 0; 4; 10 Participants
Phase 1 N=59 Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Malignant Glioma · Recurrent Brain Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: Number of Dose Limiting Toxicities of Selinexor — 0; 4; 1; 2 Participants
Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants